Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Appili Therapeutics faces funding reset after NIAID terminates VXV-01 contract
Appili Therapeutics faces a funding reset after NIAID ended its VXV-01 contract. Discover what the termination means for APLI investors.
Takeda is paying Insilico $600m to find drugs before humans take over
Takeda signs a $600 million Insilico AI drug deal. Read how Pharma.AI could reshape pipeline economics, R&D productivity and investor sentiment.
Why Merck KGaA is spending $11.3bn on Bio-Techne instead of another drug pipeline
Merck KGaA plans to acquire Bio-Techne for $11.3 billion. Read why laboratory tools, recurring revenue and debt-funded growth could reshape its strategy.
Could three FDA submissions turn bezuclastinib into a rare disease and oncology launch engine?
Cogent’s AdvSM NDA gives COGT a third bezuclastinib FDA submission, sharpening its KIT-driven disease franchise and late-2026 launch story.
MacroGenics exits GMP manufacturing operations as Bora expands U.S. biologics footprint
MacroGenics’ $122.5 million Bora sale boosts MGNX cash flexibility while shifting GMP manufacturing to a CDMO model.
Viridian Therapeutics (VRDN) challenges Amgen’s Tepezza with broader thyroid eye disease approval
Viridian Therapeutics wins FDA approval for Lumvoa, its first commercial product, challenging Amgen in thyroid eye disease.
Racura Oncology (ASX:RAC): Will HARNESS-1 reset its valuation?
Racura Oncology has funded three cancer trials, but RAC shares remain far below their high. HARNESS-1 must now turn clinical progress into evidence.
Vertex Pharmaceuticals (Nasdaq: VRTX) gains FDA approval to expand Casgevy to children as young as two
Vertex Pharmaceuticals wins FDA approval to expand Casgevy to children as young as two, reshaping sickle cell treatment economics.
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
Could nomlabofusp become the rare disease catalyst that revalues Larimar?
Larimar’s rolling BLA and nomlabofusp data sharpen LRMR’s rare disease biotech story around Friedreich’s ataxia, frataxin and accelerated approval.